+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06607939

Study of ORB-021 Delivered by Intravenous Infusion in Adults with Advanced Solid Tumors Evaluating Safety and Dose Escalation

Led by Orionis Biosciences Inc · Updated on 2026-08-26

36

Participants Needed

2

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying ORB-021, an investigational new drug developed by Orionis Biosciences, to evaluate its safety and tolerability in people with advanced solid tumors. This Phase 1 clinical trial aims to determine the biologically optimal dose by assessing the drugs safety and potential activity in treating these tumors. The study involves three phases screening, treatment, and end of treatment. ORB-021 is a specially engineered biologic molecule designed to target cytokine activation specifically to certain immune cells, potentially reducing side effects. It is given through intravenous IV infusion. Participants in the dose escalation phase will receive increasing doses of ORB-021 across up to five cohorts to identify the recommended dose for future studies. Participants will undergo screening to confirm eligibility before receiving ORB-021 through IV infusion. The study team will monitor adverse events and other safety measures for up to 12 months. Researchers will also determine the recommended phase 2 dose and track any side effects throughout the study period. Participants organ function, performance status, and other health factors will be regularly assessed during the trial.

CONDITIONS

Brief Title

ORB-021 In Patients With Advanced Solid Tumors

Research Team

J

Jennifer Hertzog, PhD

A

Azza Gadir, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here